Mutaciones de BRAF:
2014-2016
Pietrantonio F, Petrelli F, Coinu A et al. Predictive role of BRAF mutations in patients with advanced colorectal cancer
receivingcetuximab and panitumumab: a meta-analysis. Eur J Cancer 2015; 51: 587–594.
Rowland A, Dias MM, Wiese MD et al. Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR
monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer. Br J Cancer 2015; 112: 1888–1894
.
•
VALOR PRONÓSTICO Y SELECCIÓN DE
PACIENTES PARA ESTUDIOS CLINICOS
•
FACTOR PREDICTIVO negativo a anti
EGFR:
•
Lineas tardias evidencia acumulada
•
Primera línea: CONTROVERTIDO
